Promising anti-HIV compounds in preclinical or early clinical development.
Litterst
C
C
Drug Development and Surveillance Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015704:CD4 Antigens / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology
D000998:Antiviral Agents; D015704:CD4 Antigens; D018894:Reverse Transcriptase Inhibitors